Targeted therapy of newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. A single-center ambispective cohort study

Targeted therapy of newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. A single-center ambispective cohort study

Background. FMS‑like tyrosine kinase 3 (FLT3) gene mutations are the most frequently detected genetic aberrations in adult patients with newly diagnosed acute myeloid leukemia (AML), identified in approximately 30 % of patients. The addition of midostaurin, an FLT3 tyrosine kinase inhibitor, to stan...

Full description

Saved in:
Bibliographic Details
Main Authors: N. K. Pastukhov, S. N. Bondarenko, A. G. Smirnova, Yu. Yu. Vlasova, D. K. Zhogolev, B. I. Ayubova, O. G. Smykova, N. P. Volkov, I. S. Moiseev, A. D. Kulagin
Format: Article
Language:Russian
Published: ABV-press 2025-03-01
Series:Онкогематология
Subjects:
acute myeloid leukemia
<i>flt3</i> mutation
targeted therapy
midostaurin
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/1004
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://oncohematology.abvpress.ru/ongm/article/view/1004

Similar Items